Disclosed herein are compositions and methods of treating a spinal cord injury and improving spinal cord function. Also disclosed are compositions and methods of stimulating regeneration, promoting glial cell proliferation, promoting axonal tract regeneration, triggering neurite outgrowth, and triggering neuron formation in injured and/or damaged spinal cord tissue.

Provided is a method for identifying a substance capable of affecting aging, the method comprising: determining the effect of a candidate substance on the activity and/or expression of Zip11; and identifying the candidate substance that changes the activity and/or expression of Zip11 as a substance capable of affecting aging. Further provided is the use of a substance capable of increasing the activity and/or expression quantity of Zip11 for preparing a medicine, wherein the medicine is used for delaying or ameliorating aging.

An information processing apparatus according to the present application includes: an acquisition unit configured to acquire individual information indicating a characteristic of behavior of an individual belonging to a group of living organisms to be processed arranged in a virtual space, relative information indicating a characteristic of the behavior relative to the individuals of other individuals located around the individual belonging to the group of living organisms to be processed with respect to the individual, and environmental information indicating a characteristic of an environment around the individual belonging to the group of living organisms to be processed; and a determination unit configured to determine a behavior of an individual belonging to the group of living organisms to be processed on the basis of the individual information, the relative information, and the environmental information acquired by the acquisition unit.

This disclosure describes exemplary embodiments of a method of creating a YY animal broodstock, preferably in a single generation, wherein the broodstock includes only sperm-producing YY males and egg-producing YY males, the method comprising the steps of: (a) creating YY males via androgenesis; (b) exposing selected ones of the YY males created in step (a) to a feminizing hormone; and (c) identifying sperm-producing YY males and egg-producing YY males from among the YY males created in steps (a) and (b). In other embodiments, the method further comprises: (d) repeating steps (a) through (c) N times in order to produce N unrelated families of sperm-producing YY males and egg-producing YY males; and (e) cross-breeding various ones of the unrelated families produced in step (d) in order to produce a genetically-diverse YY progeny. In some embodiments, N may be about 60.

A method of constructing a zebrafish notch1a mutant using CRISPR/Cas9 technique. The method includes: determining a target for knocking out notch1a; using primers T7-notch1a-sfd and tracr rev for PCR amplification with a pUC19-gRNA scaffold plasmid as a template; transcribing PCR product in vitro followed by purification to obtain gRNA; and microinjecting the gRNA and a Cas9 mRNA into a zebrafish embryo followed by culture to obtain an notch1a mutant of stable inheritance. The invention selects a specific target and utilizes CRISPR/Cas9 technique to knock out the notch1a in the zebrafish without destroying other genes, generating the zebrafish notch1a mutant. Moreover, the invention also discloses the phenotype of the zebrafish notch1a mutant, which plays a significant role in studying the effect of the Notch1a receptor in the Notch signaling pathway.

A tumor cell xenograft model in zebrafish, and methods of constructing and using the same. Primary cells dissociated from the tumor tissue of a patient are transplanted into zebrafish, so as to obtain a patient-derived tumor xenograft model. The tumor xenograft model retains the pathological features of human gastric cancer tissues in clinic, has higher clinical relevance, and can be used in the systematic research into the mechanisms underlying the proliferation, metastasis, spread and drug resistance of tumors, and to screen effective drugs for tumor treatments.

Hybrid fish thumper-scale devices. A hybrid fish thumper-scale device includes a barrel configured to stun a fish by striking the fish with the barrel, a handle rigidly coupled to the barrel and configured to be gripped by a user, and a weighing scale configured to provide an indication of the weight of the fish. The weighing scale includes a fixed portion rigidly coupled to the handle and a mobile portion elastically coupled to the handle.

Methods, uses, and compositions for manipulating genomic DNA. Some of the embodiments of the invention provide for making a founder animal that is completely free of all unplanned genetic modifications. Some embodiments are directed to removing genetic faults in established breeds without making other alterations to the genome. Other embodiments are directed to particular tools or processes such as TALENs or CRISPR with a preferred truncation. One embodiment involves introducing a targeted targeting endonuclease system and a HDR template into a cell (optionally with a mismatch in the binding of the targeting endonuclease and the targeted site). Another embodiment includes processes of making a genetically modified livestock animal comprising a genome that comprises inactivation of a neuroendocrine gene selective for sexual maturation, with the inactivation of the gene preventing the animal from becoming sexually mature. One embodiment includes compositions and methods for making livestock with a polled allele, including migrating a polled allele into a bovine species without changing other genes or chromosomal portions.

Provided herein are methods for the prevention and treatment of an abnormal tissue condition in the liver (e.g., liver cancer) of a subject, based on the administration of an inhibitor of a G protein-coupled estrogen receptor 1 (GPER1).

An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid receptor agonistic activity (for example, tamibarotene, tamibarotene methyl ester, tamibarotene ethyl ester, tazarotene, tazarotenic acid, adapalene, palovarotene, retinol, isotretinoin, alitretinoin, etretinate, acitretin or bexarotene) or a salt thereof.